Current Pipeline
We are building a risk-diversified neuroinflammation portfolio combining multiple upstream mechanisms, advanced in parallel to maximize translational potential and early partnering opportunities.
Why Neuroinflammation?
Neuroinflammation is a shared mechanistic axis across multiple CNS disorders
0
neurological disorders
1
individuals affected during their lifetime
the medical and societal burden is substantial.
Targeting upstream inflammatory mechanisms offers the unique opportunity to
address shared biology across multiple brain disorders
pursue disease-modifying approaches rather than symptomatic management
generate strong partnering and lifecycle value through differentiated biology
This scientific perspective is increasingly validated by growing academic literature,
biomarker advances and rising pharma interest in neuroinflammation.